Latest ROE for Cumberland Pharmaceuticals: -60.82% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-60.82%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Cumberland Pharmaceuticals (CPIX) currently reports a ROE of -60.82%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore Cumberland Pharmaceuticals's ROE history and peer comparisons.
Cumberland Pharmaceuticals's ROE of -60.82% is lower than the Healthcare sector average of 21.67%. That is roughly 380.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Cumberland Pharmaceuticals's current -60.82% should be judged against Healthcare norms (sector average: 21.67%) and against CPIX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -60.82%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Cumberland Pharmaceuticals, and consider following CPIX for alerts when major investors trade the stock.
Cumberland Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows -60.82% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CPIX with unrelated industries.